• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Canvas
• Praxis
• Urban Pulse
• Brand Quest
• The New Manager

Stocks

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

Cross Currency

• Rates
  
  

Shipping

• Ports
  
  

Archives

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth

Group Sites

• The Hindu
• The Hindu ePaper
• Business Line
• Business Line ePaper
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

Our Bureau

New Delhi, March 20

Pharmaceutical research firm Jubilant Organosys Ltd said it has added custom research and manufacturing services (CRAMS) contracts worth $60 million to its 2007 order book.

Ninety per cent of the contracts are from drug firms based in regulated markets of the US and Europe, it said in a statement.

"The addition of these annual contracts reaffirms our global position in CRAMS. Going forward, we will continue to focus on the twin strategies of investments in innovation and world-class manufacturing facilities, as key competitive differentiators," Jubilant Organosys Chairman and Managing Director Mr Shyam S. Bhartia said in the statement.

He said the company is in advanced talks with several other global life sciences companies for CRAMS activities.

More Stories on : New Business | Pharmaceuticals

Article E-Mail :: Comment :: Syndication :: Printer Friendly Page

Stories in this Section
AstraZeneca winds up research society

Copyright © 2007, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line